These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

347 related articles for article (PubMed ID: 29249252)

  • 21. Janus Kinase Inhibitors in Dermatology: Part 2: Applications in Psoriasis, Atopic Dermatitis, and Other Dermatoses.
    Garcia-Melendo C; Cubiró X; Puig L
    Actas Dermosifiliogr (Engl Ed); 2021; 112(7):586-600. PubMed ID: 34030992
    [TBL] [Abstract][Full Text] [Related]  

  • 22. JAK-STAT signaling pathway inhibition: a role for treatment of various dermatologic diseases.
    Kahn J; Deverapalli SC; Rosmarin D
    Semin Cutan Med Surg; 2018 Sep; 37(3):198-208. PubMed ID: 30215638
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [What's new in dermatological treatments?].
    Martin L
    Ann Dermatol Venereol; 2010 Dec; 137 Suppl 4():S165-76. PubMed ID: 21193120
    [TBL] [Abstract][Full Text] [Related]  

  • 24. JAK/STAT pathway modulation: Does it work in dermatology?
    Gündüz Ö
    Dermatol Ther; 2019 May; 32(3):e12903. PubMed ID: 30964573
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Current and upcoming treatments of adult atopic dermatitis].
    Lacour JP
    Ann Dermatol Venereol; 2017 Dec; 144 Suppl 5():VS29-VS37. PubMed ID: 29433635
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Biologics for chronic inflammatory skin diseases: an update for the clinician.
    Yao Y; Ravn Jørgensen AH; Thomsen SF
    J Dermatolog Treat; 2020 Mar; 31(2):108-130. PubMed ID: 30827126
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Off-label uses of TNF-a inhibitors and IL-12/23 inhibitors in dermatology.
    Hong JJ; Hadeler EK; Mosca ML; Brownstone ND; Bhutani T; Liao WJ
    Dermatol Online J; 2021 Nov; 27(11):. PubMed ID: 35130397
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Emerging therapies for atopic dermatitis: JAK inhibitors.
    Cotter DG; Schairer D; Eichenfield L
    J Am Acad Dermatol; 2018 Mar; 78(3 Suppl 1):S53-S62. PubMed ID: 29248518
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Targeting the Janus Kinase Family in Autoimmune Skin Diseases.
    Howell MD; Kuo FI; Smith PA
    Front Immunol; 2019; 10():2342. PubMed ID: 31649667
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [What's new in pediatric dermatology?].
    Mazereeuw-Hautier J
    Ann Dermatol Venereol; 2018 Dec; 145 Suppl 7():VIIS32-VIIS46. PubMed ID: 30583755
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [What's new in dermatological research?].
    Seneschal J
    Ann Dermatol Venereol; 2016 Dec; 143 Suppl 3():S19-S22. PubMed ID: 29429505
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Janus kinase inhibitors : Indications, efficacy, uses, what should be taken into account?].
    von Martial S; Tsianakas A
    Dermatologie (Heidelb); 2024 Mar; 75(3):256-267. PubMed ID: 38100043
    [TBL] [Abstract][Full Text] [Related]  

  • 33. JAK-inhibitors in dermatology - small molecules, big impact? Overview of the mechanism of action, previous study results and potential adverse effects.
    Klein B; Treudler R; Simon JC
    J Dtsch Dermatol Ges; 2022 Jan; 20(1):19-24. PubMed ID: 34962052
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Analysis of patient experiences regarding JAK inhibitors for atopic dermatitis, psoriasis, alopecia areata, and vitiligo.
    Sharma D; Gart S; Kitrell B; Lonowski S; Arthur M; Wei EX
    Arch Dermatol Res; 2024 Sep; 316(9):630. PubMed ID: 39292291
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Dermatology - Latest developments in targeted therapies for atopic dermatitis, alopecia areata and chronic spontaneous urticaria].
    Piletta-Zanin A; Hsieh A; Mühlstädt M; Andenmatten-Trigona B
    Rev Med Suisse; 2022 Feb; 18(767):156-160. PubMed ID: 35107888
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Emerging Topical and Systemic JAK Inhibitors in Dermatology.
    Solimani F; Meier K; Ghoreschi K
    Front Immunol; 2019; 10():2847. PubMed ID: 31849996
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [What's new in clinical dermatology?].
    Barbaud A
    Ann Dermatol Venereol; 2014 Dec; 141 Suppl 4():S597-609. PubMed ID: 25539751
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comorbidities in Dermatology: What's Real and What's Not.
    Qureshi A; Friedman A
    Dermatol Clin; 2019 Jan; 37(1):65-71. PubMed ID: 30466689
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [What's new in dermatological treatments?].
    Ortonne JP
    Ann Dermatol Venereol; 2008 Dec; 135 Suppl 7():S360-70. PubMed ID: 19264212
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Overview of Safety, Efficacy, and Patient Counseling for Ruxolitinib in Treating Atopic Dermatitis.
    Mancuso-Stewart E; Rodger J; Zirwas M
    Skinmed; 2023; 21(1):40-43. PubMed ID: 36987827
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.